Bioverativ
225 Second Avenue
Waltham
Massachusetts
02451
United States
Tel: 781-663-4400
Website: https://www.bioverativ.com/
About Bioverativ
Launching in 2017, Bioverativ will build on Biogen’s leading hemophilia business to transform the lives of people with hemophilia and other rare blood disorders.YEAR FOUNDED:
2017
LEADERSHIP:
CEO: John Cox
66 articles about Bioverativ
-
rHEALTH Announces Ongoing Collaboration With Bioverativ
3/7/2017
-
Bioverativ Release: Long-term Safety And Efficacy Extension Study Data Of ALPROLIX For Hemophilia B Published In Thrombosis And Hemostasis
3/2/2017
-
Anna Protopapas To Join Bioverativ Board Of Directors
3/2/2017
-
Bioverativ Release: Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy ALPROLIX In Children With Hemophilia B Published In The Lancet Hematology
2/2/2017
-
Biogen Completes Separation Of Global Hemophilia Business, Bioverativ
2/1/2017
-
Launching This Week, A Look at Biogen's Spinoff Bioverativ
1/30/2017